(089) Female Ejaculation, Squirting, and Coital Incontinence: A Systematic Review and Meta-Analysis of Biochemical, Imaging, and Urodynamic Diagnostic Criteria

Introduction Fluid expulsion during sexual activity presents a diagnostic challenge in sexual medicine. Distinguishing physiological phenomena-female ejaculation and squirting-from pathological coital incontinence (CI) is critical, as misdiagnosis leads to inappropriate treatment of normal sexual responses. Women experiencing orgasmic fluid expulsion have been misdiagnosed with urinary incontinence, resulting in unnecessary interventions and psychosexual distress. Evidence-based diagnostic criteria integrating biochemical, imaging, and urodynamic findings are essential. Objective To systematically review and synthesize biochemical composition, anatomical origin, and urodynamic characteristics of fluids expelled during female sexual activity, establishing diagnostic criteria to differentiate female ejaculation, vaginal squirting, and coital incontinence. Methods A comprehensive literature search was conducted through PubMed, Scopus and Web of Science databases. Eligible studies provided biochemical assays (prostate-specific antigen [PSA], prostatic acid phosphatase [PAP], urea, creatinine), diagnostic imaging (ultrasound, indigo-carmine dye studies), patient-reported characteristics, or urodynamic parameters (stress urinary incontinence [SUI], detrusor overactivity [DOA], abdominal leak point pressure). Random-effects meta-analysis was performed where feasible. Results A total of 17 studies were eligible for our study including 342 cases. Regarding the biochemical composition and anatomical origin, three studies were included in the meta-analysis reporting the expelled fluids. Female ejaculation was consistently characterized in these studies as small-volume (1–5 mL), whitish, viscous fluid with elevated PSA (pooled mean: 42.6 ng/mL; 95% CI: 35.2–50.0 ng/mL) and minimal urinary solutes (urea <5 mg/dL, creatinine <0.1 mg/dL), confirming a paraurethral (Skene’s gland) source. In contrast, vaginal squirting, documented in the same and additional datasets, consisted of large-volume (median 60 mL, range 15–900 mL) clear fluid with high urea (pooled mean: 172 mg/dL; 95% CI: 150–194 mg/dL) and creatinine (pooled mean: 30 mg/dL; 95% CI: 25–35 mg/dL) comparable to urine, with fluid:serum creatinine ratios >1.0 for squirting versus <0.05 for ejaculation (p < 0.001), confirming bladder origin. Imaging and visualization results from four studies showed real-time ultrasound evidence of bladder filling during arousal and complete emptying concurrent with squirting. Indigo-carmine dye studies confirmed transurethral expulsions during squirting episodes, affirming that both female ejaculation and squirting represent physiological, non-pathological processes rather than involuntary incontinence. For urodynamic differentiation, ten studies addressed coital incontinence (CI) as a pathological outcome. Among women with CI at penetration (CIAP), 89.4% demonstrated stress urinary incontinence (SUI) on urodynamic testing. Those with CI at orgasm (CIAO) showed detrusor overactivity (DOA) in 69.4% of cases. Severity of CI was negatively correlated with abdominal leak point pressure (r = –0.36, p = 0.01). Women with only physiological fluid expulsion (ejaculation or squirting) exhibited no SUI or DOA on provocative testing. Interviews indicated that those with CI described involuntary, distressing loss identical to urination, whereas those with physiological phenomena reported high arousal and satisfaction. Conclusions Female ejaculation (PSA-positive, urea/creatinine-negative, paraurethral origin) and squirting (urea/creatinine-positive, bladder origin) represent physiological responses requiring no intervention. Coital incontinence is pathological, confirmed by urodynamic abnormalities (SUI for CIAP; DOA for CIAO). Clinical application of these biochemical, imaging, and urodynamic criteria prevents misdiagnosis, avoids inappropriate treatment of normal sexual function, and ensures appropriate management for pathological CI. Disclosure No